Advertisement

Volume 1, Issue 23

 

Cover Image

Cover Figure:  Gene ontology network, generated by Biological Networks Gene Ontology analysis.
See the article by Xiao et al.

WASHINGTON, October 24,  2017 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

Cadherin-17 is a member of the cadherin superfamily known to be involved in B-cell development. In this Exceptional Case Report, the Blazar group discusses a patient with a cadherin-17 mutation resulting in severe combined immune deficiency and their successful treatment of this patient with an allogeneic hematopoietic cell transplantation.

 

The relationship between a venous thromboembolism (VTE) and occult cancer is well established. However, much less is known when a VTE occurs during pregnancy. In the Stimulus Report by Hansen and colleagues this relationship is explored with interesting and provocative findings.

Daratumumab (anti-CD38 monoclonal antibody) is a new, effective treatment for patients with relapsed and refractory multiple myeloma. It is well recognized that natural killer (NK) cells may participate in antibody-dependent cellular cytotoxicity and play an important role in the effectiveness of daratumumab. Casneuf et al explored the impact of daratumumab treatment on NK cell number and function, demonstrating that NK cells decrease but remain functional following treatment with this agent.

 

 

As gene therapy for hematological diseases gains momentum in the clinic, a persistent challenge has been the efficient transduction of hematopoietic stem cells without compromising their biological potential. In the paper by Levy et al, measles virus glycoproteins displaying lentiviral vectors were demonstrated to transduce nearly 100% of CD34+ progenitor cells. This remarkable achievement may set the stage for much more efficient clinical applications.

It is well recognized that patients with myelodysplastic syndromes are at increased risk of progression to acute leukemia and death. Brunner and colleagues demonstrate that another major cause of death is from cardiovascular disease. This highlights the potential for interesting interactions between hematological and heart disease and the need to be vigilant about cardiovascular disease associated risk factors.

 


Featured Visual Abstract

Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors

Amine Meliani, Florence Boisgerault, Zachary Fitzpatrick, SolenneMarmier, Christian Leborgne, Fanny Collaud, Marcelo Simon Sola, Severine Charles, Giuseppe Ronzitti, Alban Vignaud, Laetitia van Wittenberghe, Beatrice Marolleau, Fabienne Jouen, Sisareuth Tan, Olivier Boyer, Olivier Christophe, Alain R. Brisson, Casey A. Maguireand Federico Mingozzi

 

 

 

 

Blood Advances is the open-access journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.